Kazia Therapeutics ROCE
Was ist das ROCE von Kazia Therapeutics?
ROCE von Kazia Therapeutics Limited ist 0.00%
Was ist die Definition von ROCE?
Die Kapitalerträge (ROCE) entsprechen einer Finanzkennzahl, die die Rentabilität eines Unternehmens und die Effizienz, mit der sein Kapital verwendet wird, misst.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE von Unternehmen in Health Care Sektor auf ASX im Vergleich zu Kazia Therapeutics
Was macht Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Unternehmen mit roce ähnlich Kazia Therapeutics
- Omega Alpha Spac hat ROCE von -0.01%
- The Gap hat ROCE von -0.01%
- Elemental Royalties Ltd hat ROCE von -0.01%
- Auburn National Bancorp hat ROCE von -0.01%
- Galaxy Digital hat ROCE von -0.01%
- The Gap hat ROCE von -0.01%
- Kazia Therapeutics hat ROCE von 0.00%
- Tejon Ranch Co hat ROCE von 0.01%
- Glen Burnie Bancorp hat ROCE von 0.02%
- MSP Steel & Power hat ROCE von 0.02%
- TTL Beteiligungs- und Grundbesitz-AG hat ROCE von 0.03%
- First Foundation Inc hat ROCE von 0.03%
- FirstMark Horizon Acquisition hat ROCE von 0.03%